Crinetics Pharmaceuticals Announces New Stock Option Grants
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced a new round of non-qualified stock option awards that underscores its focus on employee growth and long-term engagement. In September, the company told stakeholders that it had granted options covering 120,200 shares of common stock to fifteen newly hired, non-executive employees. The awards were made under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan, a program created to attract and motivate talent joining the organization.
What the 2021 Inducement Plan Enables
The 2021 Inducement Plan is designed for equity grants to individuals who weren’t previously employed by Crinetics. It’s aligned with Nasdaq Listing Rule 5635(c)(4), which permits the use of equity awards as a material inducement to employment. In practice, it helps the company bring in new hires with a clear, equity-based stake in its future. The options were granted with an exercise price of $50.40 per share, matching the closing price on the date of the announcement.
How the Options Vest
The vesting schedule runs over four years. Here’s how it works: 25% of the shares vest on the first anniversary of the vesting commencement date. The remaining 75% then vest in equal monthly installments over the next three years. This cadence rewards tenure and encourages continued service, while giving employees a steady path to ownership over time.
About Crinetics Pharmaceuticals
Crinetics develops therapies for endocrine diseases and tumors, with a focus on areas of significant unmet need. The company’s lead candidate is paltusotine, an oral somatostatin receptor type 2 (SST2) agonist. Paltusotine is in Phase 3 clinical trials for acromegaly and in Phase 2 for carcinoid syndrome associated with neuroendocrine tumors. As a clinical-stage company, Crinetics concentrates on advancing programs that aim to make treatment more accessible and practical for patients.
Pipeline Progress
Beyond paltusotine, Crinetics is developing atumelnant (CRN04894), an oral ACTH antagonist now in Phase 2 studies for conditions such as congenital adrenal hyperplasia and Cushing’s disease. The company is also pursuing discovery efforts in other endocrine disorders, including hyperparathyroidism and polycystic kidney disease. The goal is straightforward: build a pipeline that addresses tough, often overlooked problems in endocrinology.
Investor Relations
Crinetics maintains open communication with investors. Gayathri Diwakar, Head of Investor Relations, leads these efforts and is available to field questions and provide updates on performance and strategy. The company emphasizes clarity, timely information, and steady dialogue with its investor base.
Media Contacts
For media inquiries, corporate communications are led by Natalie Badillo. She supports the company’s storytelling around its programs and progress so that stakeholders and the public have a clear, consistent view of where Crinetics is headed and why it matters.
Frequently Asked Questions
Why did Crinetics grant these stock options?
The options are part of the 2021 Employment Inducement Incentive Award Plan and are intended to attract and retain new, non-executive hires by giving them a direct stake in the company’s future.
Who received the awards and how many shares are covered?
Fifteen newly appointed non-executive employees received options covering a total of 120,200 shares of Crinetics common stock.
How was the exercise price determined?
The exercise price was set at $50.40 per share, which matched the closing price of Crinetics common stock on the announcement date, consistent with standard equity grant practices.
What is the vesting schedule for these options?
Twenty-five percent of the shares vest on the first anniversary of the vesting commencement date. The remaining 75% vest in equal monthly installments over the following three years.
What programs are currently leading Crinetics’ pipeline?
Paltusotine, an oral SST2 agonist, is in Phase 3 for acromegaly and Phase 2 for carcinoid syndrome associated with neuroendocrine tumors. Atumelnant (CRN04894), an oral ACTH antagonist, is in Phase 2 for conditions including congenital adrenal hyperplasia and Cushing’s disease, with additional discovery work in disorders such as hyperparathyroidism and polycystic kidney disease.
